BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

...of its proposed range.FDA approves generic sedative in short supplyFDA has approved an ANDA from Par Pharmaceutical...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...Products division of Par Pharmaceutical Inc., a subsidiary of Endo. Ciarico succeeds Tony Pera, president of Par Pharmaceutical...
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...chloride channel activator. Under a 2014 settlement regarding patent litigation for Amitiza, Sucampo granted the Par Pharmaceutical...
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...chloride channel activator. Under a 2014 settlement regarding patent litigation for Amitiza, Sucampo granted the Par Pharmaceutical...
BioCentury | Nov 30, 2017
Company News

Omeros, Par settle Omidria patent infringement lawsuit

...Corp. (NASDAQ:OMER), Seattle, Wash. Endo International plc (NASDAQ:ENDP), Dublin, Ireland Business: Ophthalmic Allison Johnson Omidria Endo International plc Omeros Corp. Par Pharmaceutical Adrenergic...
BioCentury | Apr 21, 2017
Company News

BioMarin, Par settlement deal

...BioMarin granted Endo's Par Pharmaceutical company non-exclusive U.S. rights to market Kuvan sapropterin as a generic starting...
BioCentury | Nov 8, 2016
Company News

Management tracks

...named Terrance Coughlin EVP and COO. Endo also named Tony Pera as president of its Par Pharmaceutical...
BioCentury | Sep 23, 2016
Company News

Management tracks

...Endo named Paul Campanelli as his successor in both roles. Campanelli was president of Endo's Par Pharmaceutical Holdings Inc....
BioCentury | Feb 8, 2016
Company News

Acorda, Endo deal

...Acorda granted Endo’s Par Pharmaceutical Inc. company rights to market a generic version of Acorda’s Ampyra dalfampridine...
BioCentury | Nov 9, 2015
Company News

Supernus, Endo deal

...Supernus granted Endo’s Par Pharmaceutical company rights to sell the generic version of Trokendi XR topiramate starting...
Items per page:
1 - 10 of 197
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

...of its proposed range.FDA approves generic sedative in short supplyFDA has approved an ANDA from Par Pharmaceutical...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...Products division of Par Pharmaceutical Inc., a subsidiary of Endo. Ciarico succeeds Tony Pera, president of Par Pharmaceutical...
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...chloride channel activator. Under a 2014 settlement regarding patent litigation for Amitiza, Sucampo granted the Par Pharmaceutical...
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...chloride channel activator. Under a 2014 settlement regarding patent litigation for Amitiza, Sucampo granted the Par Pharmaceutical...
BioCentury | Nov 30, 2017
Company News

Omeros, Par settle Omidria patent infringement lawsuit

...Corp. (NASDAQ:OMER), Seattle, Wash. Endo International plc (NASDAQ:ENDP), Dublin, Ireland Business: Ophthalmic Allison Johnson Omidria Endo International plc Omeros Corp. Par Pharmaceutical Adrenergic...
BioCentury | Apr 21, 2017
Company News

BioMarin, Par settlement deal

...BioMarin granted Endo's Par Pharmaceutical company non-exclusive U.S. rights to market Kuvan sapropterin as a generic starting...
BioCentury | Nov 8, 2016
Company News

Management tracks

...named Terrance Coughlin EVP and COO. Endo also named Tony Pera as president of its Par Pharmaceutical...
BioCentury | Sep 23, 2016
Company News

Management tracks

...Endo named Paul Campanelli as his successor in both roles. Campanelli was president of Endo's Par Pharmaceutical Holdings Inc....
BioCentury | Feb 8, 2016
Company News

Acorda, Endo deal

...Acorda granted Endo’s Par Pharmaceutical Inc. company rights to market a generic version of Acorda’s Ampyra dalfampridine...
BioCentury | Nov 9, 2015
Company News

Supernus, Endo deal

...Supernus granted Endo’s Par Pharmaceutical company rights to sell the generic version of Trokendi XR topiramate starting...
Items per page:
1 - 10 of 197